WO2022177054A1 - Composition pharmaceutique pour la prévention ou le traitement d'une infection par le coronavirus 2 responsable du syndrome respiratoire aigu sévère - Google Patents

Composition pharmaceutique pour la prévention ou le traitement d'une infection par le coronavirus 2 responsable du syndrome respiratoire aigu sévère Download PDF

Info

Publication number
WO2022177054A1
WO2022177054A1 PCT/KR2021/002974 KR2021002974W WO2022177054A1 WO 2022177054 A1 WO2022177054 A1 WO 2022177054A1 KR 2021002974 W KR2021002974 W KR 2021002974W WO 2022177054 A1 WO2022177054 A1 WO 2022177054A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
naphthalen
yloxy
hydroxy
octenediamide
Prior art date
Application number
PCT/KR2021/002974
Other languages
English (en)
Korean (ko)
Inventor
김영대
조재평
조중명
Original Assignee
크리스탈지노믹스(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스탈지노믹스(주) filed Critical 크리스탈지노믹스(주)
Publication of WO2022177054A1 publication Critical patent/WO2022177054A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating type 2 severe acute respiratory syndrome coronavirus infection containing alkylcarbamoyl naphthalenyloxy octenoyl hydroxyamide, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. it's about
  • COVID-19 SARS-CoV-2 virus infectious disease
  • MERS MERS
  • SARS, MERS, and COVID-19 which are a kind of coronavirus, cause animal-human cross-species infection and cause sepsis, pneumonia, acute lung injury syndrome, Acute Respiratory Distress Syndrome (ARDS), and cytokine release. It can cause serious conditions such as Cytokine Release Syndrome (CRS) and can lead to death.
  • CRS Cytokine Release Syndrome
  • ARDS acute respiratory distress syndrome
  • ARDS is an acute pulmonary inflammatory syndrome caused by a homeostatic disruption of the immune system, such as cytokine release syndrome.
  • Cytokine release syndrome induces the release of large amounts of inflammatory cytokines by various cells, including non-immune cells and immune cells, and, in severe cases, causes death. Therefore, it is urgent to develop a treatment that can reduce the mortality rate by reducing the severity of acute respiratory distress syndrome and cytokine release syndrome.
  • the present inventors have confirmed the effect that the alkylcarbamoyl naphthalenyloxy octenoyl hydroxyamide of a specific formula, a derivative thereof, or a pharmaceutically acceptable salt thereof inhibits and improves the type 2 severe acute respiratory syndrome coronavirus infection.
  • the invention was completed.
  • An object of the present invention is a pharmaceutical for the prevention or treatment of type 2 severe acute respiratory syndrome coronavirus infection containing alkylcarbamoyl naphthalenyloxy octenoyl hydroxyamide, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. to provide a composition.
  • the present invention in order to solve the above problems,
  • compositions for preventing or treating type 2 severe acute respiratory syndrome coronavirus infection comprising a compound of Formula 1, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
  • R 1 is halophenyl, C 1-3 alkoxy, C 1-3 alkoxy C 1-3 alkyl, cyclohexanyl, furanyl, thiophenyl, imidazole, imidazolidyl C 1-3 alkyl, C 1-3 alkylamino, diC1-3alkylamino, hydroxyphenyl, tetrahydrofuranyl, cyclohexyl, cyclohexenyl, oxopyrrolidinyl, C1-3alkoxyphenyl, diC1-3alkylaminophenyl, C1-3alkylpyrrolidinyl and C 1-3 alkyl unsubstituted or substituted with one or more substituents selected from the group consisting of trifluoromethoxyphenyl;
  • the compound of Formula 1 is selected from the group consisting of the following compounds.
  • the compound of Formula 1 is (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy) represented by Formula 2 methyl)oct-2-enediamide ((E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide) .
  • the pharmaceutically acceptable salts are phosphate, tartrate, stearate, gluconate, fumarate, naphthoate, and 1-hydroxy-2-naphthoic acid salt (1-Hydroxy- 2-naphthoic acid) may be at least one selected from the group consisting of.
  • the pharmaceutical composition according to the present invention may be in the form of a capsule, tablet, granule, injection, ointment, powder or beverage.
  • the pharmaceutical composition according to the present invention may be targeted to mammals such as rats, mice, livestock, and humans.
  • composition according to the present invention is not limited thereto, but oral dosage forms such as powders, granules, capsules, tablets, aqueous suspensions, emulsions, powders, and dry syrups, external preparations, suppositories, and injections, respectively, are prepared according to conventional methods. It can be formulated and used in the form.
  • the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, dyes, fragrances, etc., for oral administration, and in the case of injections, buffers, preservatives, pain-freezing agents
  • a topical agent, solubilizer, isotonic agent, stabilizer, etc. may be mixed and used.
  • a base, excipient, lubricant, preservative, etc. may be used for topical administration.
  • the dosage form of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with a pharmaceutically acceptable carrier as described above.
  • oral administration in the case of oral administration, it can be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, it can be prepared in the form of unit dose ampoules or multiple doses. have.
  • it can be formulated as a solution, suspension, tablet, capsule, sustained release formulation, and the like.
  • the pharmaceutical composition for oral administration includes one or more diluents selected from the group consisting of microcrystalline cellulose, mannitol, lactose and lactose, talc, magnesium stearate, sodium stearyl fumarate, and one selected from the group consisting of glyceryl behenate. At least one binder selected from the group consisting of the above lubricants, polyvinylpyrrolidone, hydroxypropylmethylcellulose and hydroxypropylcellulose may be included.
  • the coating layer may be included in an amount of 1 to 10% by weight based on 100 parts by weight of the tablet or capsule.
  • the coating layer may include a water-soluble coating base, and a commonly used coating base may be used.
  • it may include a coating base comprising a polyvinyl alcohol derivative, a methacrylic acid derivative, and a polyacrylic acid derivative, and for example, Opadry®, Kollicoat®, and hydroxypropyl methyl cellulose (HPMC).
  • a coating base comprising a polyvinyl alcohol derivative, a methacrylic acid derivative, and a polyacrylic acid derivative
  • HPMC hydroxypropyl methyl cellulose
  • a pharmaceutical excipient having excellent compounding compatibility with the compound may be added.
  • the alkylcarbamoyl naphthalenyloxy octenoyl hydroxyamide component is a water-soluble substance that dissolves well in water, so it can be provided in a liquid form. This is not essential, and since mixing compatibility with additives may be unstable, it is preferable to use a minimum of additives, and more specifically, it can be prepared by dissolving in nitrogen-purged water for injection and then freeze-drying.
  • the sterilization method may include dry heat sterilization, pressure or reduced pressure sterilization, filter sterilization, gas sterilization, radiation sterilization, and the like.
  • a nitrocellulose membrane filter may be used, for example, a filter of 0.45um, 0.2um, etc. may be used.
  • the step of sterilizing by high-temperature pressure-reducing sterilization or aseptic filtration may be further included.
  • the route of administration of the pharmaceutical composition according to the present invention is, but not limited to, oral, bronchial, intravenous, intramuscular, subcutaneous, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal. Oral or parenteral administration is preferred.
  • parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • the pharmaceutical composition of the present invention may also be administered in the form of a suppository for rectal administration.
  • any number of compound administration techniques existing in the art may be selected, including, but not limited to, oral, injection, aerosol, parenteral, and topical administration.
  • the pharmaceutical composition of the present invention varies depending on several factors including the activity of the specific compound used, age, weight, general health, sex, formula, administration time, administration route, excretion rate, drug formulation, and the severity of the specific disease to be prevented or treated
  • the dosage of the pharmaceutical composition may vary depending on the patient's condition, weight, degree of disease, administration route and period, but may be appropriately selected by those skilled in the art, and 0.0001 to 50 mg/kg or 0.001 to daily It can be administered at 50 mg/kg. Administration may be administered once a day, or may be administered in several divided doses. The above dosage does not limit the scope of the present invention in any way.
  • the pharmaceutical composition according to the present invention may be formulated as pills, dragees, capsules, liquids, gels, syrups, slurries, and suspensions.
  • the therapeutically effective amount of the compound of Formula 1 as the active ingredient of the pharmaceutical composition according to the present invention may vary depending on the age, sex, weight, and disease of the patient, but is 0.01 to 100 mg/kg, preferably 0.1 to 50 mg/kg kg can be administered once to several times a day.
  • the dosage of the compound of Formula 1 according to the present invention may be increased or decreased depending on the route of administration, the degree of disease, sex, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any way.
  • composition of the present invention may be administered simultaneously, sequentially or in reverse sequence with other therapeutic agents for type 2 severe acute respiratory syndrome coronavirus.
  • composition of the present invention may exist as a single agent together with other therapeutic agents for type 2 severe acute respiratory syndrome coronavirus or as an independent agent, for example, may be administered simultaneously or separately.
  • the pharmaceutical composition according to the present invention was confirmed to have an anti-inflammatory effect in alleviating acute pulmonary inflammatory lesions in a rodent model induced by type 2 severe acute respiratory syndrome coronavirus infection.
  • FIG. 1 is a lung photograph of a hamster nasally inoculated with a type 2 severe acute respiratory syndrome coronavirus.
  • the test was conducted by dividing into two groups. The first group was a positive control group, and the solvent was administered after nasal inoculation with type 2 severe acute respiratory syndrome coronavirus, and the second group was administered with 15 mg/kg/day of (E) after nasal inoculation with type 2 severe acute respiratory syndrome coronavirus.
  • E after nasal inoculation with type 2 severe acute respiratory syndrome coronavirus.
  • )-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide (a compound of formula 2, hereinafter "CG200745” ") was administered. Each group was euthanized on the 2nd, 4th, and 7th days after nasal inoculation with the virus, and the lungs were removed and visually compared.
  • Figure 2 is a result of comparing the histopathological state by sectioning the lungs of the type 2 severe acute respiratory syndrome coronavirus nasal inoculation hamster model.
  • the test was conducted by dividing into two groups. The first group was a positive control group, which was administered with a solvent after nasal inoculation with type 2 severe acute respiratory syndrome coronavirus, and the second group was administered with 15 mg/kg/day of CG200745 after nasal inoculation with type 2 severe acute respiratory syndrome coronavirus. administered. After euthanasia of hamsters of each group on days 2 and 4 after viral nasal inoculation, the lungs were excised and sliced for histopathological examination.
  • mice used in this test are genetically engineered mice that express the human ACE2 gene and have confirmed type 2 severe acute respiratory syndrome coronavirus infection.
  • CG200745 the lungs of the CG200745-administered group and the non-administered group were excised and type 2 severe acute respiratory syndrome coronavirus was isolated.
  • Type 2 severe acute respiratory syndrome coronavirus isolated from each group infected VERO cells and then proceeded by comparing the number of infected VERO cells.
  • Figure 5 shows 4 animals in the normal group, 5 animals in the virus administration group, 5 animals in the CG200745 15 mg/kg (CG200745) administration group after 7 days of type 2 severe acute respiratory syndrome coronavirus infection, and CG200745 30 mg/kg after the virus administration Lungs were removed from 5 animals in the kg administration group, and the degree of lesion occurrence was visually compared and read.
  • Figure 6 shows 4 animals in the normal group, 5 animals in the virus administration group, 5 animals in the CG200745 15 mg/kg (CG200745) administration group after 7 days of type 2 severe acute respiratory syndrome coronavirus infection, and CG200745 30 mg/kg after the virus administration
  • the spleens were removed from 5 animals in the kg administration group, and the degree of lesion occurrence was visually compared and read.
  • the term 'prevention' used in the present invention may refer to any action that suppresses or delays the onset of a target disease by administration of the composition.
  • the term 'improvement' may refer to any action that reduces a parameter related to a condition to be treated, for example, the severity of symptoms.
  • the terms “treat”, “treating” and “treatment” refer to a disorder, disease, or condition; or alleviate or arrest one or more of the symptoms associated with the disorder, disease, or condition; or alleviating or eradicating the cause(s) of the disorder, disease, or condition itself.
  • the term "therapeutically effective amount” refers to an amount of a compound that, upon administration of a substance, is sufficient to prevent the onset of, or alleviate to some extent one or more of its symptoms, the disorder, disease, or condition being treated. do.
  • therapeutically effective amount also means an amount of a compound sufficient to induce a biological or medical response in a cell, tissue, system, animal or human being sought by a researcher, veterinarian, physician or clinician.
  • the term “pharmaceutical composition” may be used interchangeably with “pharmaceutical composition” and “pharmaceutically acceptable composition,” and is a composition that can have a relatively non-toxic and harmless effect on a subject to be administered, It can refer to any organic or inorganic compound formulation in which side effects resulting from the composition do not reduce the efficacy of the drug, cause serious irritation to the subject to which the compound is administered, and do not impair the biological activity and properties of the compound. .
  • the term “pharmaceutically acceptable carrier”, “pharmaceutically acceptable excipient”, “physiologically acceptable carrier” or “physiologically acceptable excipient” refers to a pharmaceutically acceptable substance, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each ingredient must be “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of the pharmaceutical formulation. It should also be suitable for use in contact with tissues or organs of humans and animals, with a reasonable benefit/risk ratio, without undue toxicity, irritation, allergic reaction, immunogenicity or other problems or complications.
  • the term “pharmaceutical composition” refers to a mixture of a compound disclosed herein and other chemical ingredients, such as pharmaceutically acceptable diluents, carriers, and the like.
  • the compound can be easily administered to an organism via the pharmaceutical composition.
  • each constituent drug of the pharmaceutical composition may be a separate agent or a single agent, and the constituent drugs may be administered simultaneously, sequentially or in reverse order.
  • the pharmaceutically effective amount, administration time, administration interval, administration route, treatment period, etc. of each constituent drug of the pharmaceutical combination may be the same or different from each other.
  • Example 1 Hamster Type 2 Severe Acute Respiratory Syndrome Coronavirus Model Evaluation
  • CG200745 was administered together with camostat to suppress the death and excessive proliferation caused by the type 2 severe acute respiratory syndrome coronavirus.
  • the administered dose of CG200745 was 15 mg/kg intraperitoneally.
  • Camostat was administered orally twice a day at a dose of 30 mg/kg.
  • the positive control group is a group administered with phosphate buffer saline (PBS) as a solvent after nasal inoculation with type 2 severe acute respiratory syndrome coronavirus.
  • PBS phosphate buffer saline
  • the lungs of the positive control group and the administered group were visually compared on the 2nd and 4th days of virus infection.
  • the positive control group had an irregular lung shape compared to the CG200745 administration group, and was smaller in appearance than the CG200745 group.
  • bleeding was observed in a wide range with the naked eye, but in the case of the CG200745 administration group, it was confirmed that the bleeding was small and the range was small.
  • the extracted normal lungs and lungs infected with type 2 severe acute respiratory syndrome coronavirus were fixed with 4% paraformaldehyde, covered with paraffin, and tissue sections with a thickness of 3 ⁇ m were prepared. Hematoxylin & Eosin (H&E) staining was performed on the finished tissue sections to perform lung histopathological analysis.
  • H&E Hematoxylin & Eosin
  • spleen tissue sections were stained with Gill's hematoxylin for 5 minutes, washed with tap water, and then treated with 95% ethanol.
  • eosin staining it was stained with eosin and phloxine for 1 minute. After that, the tissue sections were dehydrated with ethanol and xylene and fixed with Canada balsam. The prepared lung tissue sections were observed with an optical microscope.
  • the lesion mainly consisted of large nuclei and cuboidal cells, and in some cases, cells forming large syncytia were observed.
  • Control #1, 2, and 3 are positive controls administered with PBS as a solvent after nasal inoculation with type 2 severe acute respiratory syndrome coronavirus.
  • the CG200745 administration group was divided into two groups, and CG200745 was administered intraperitoneally at 15 mg/kg and 30 mg/kg, respectively.
  • the positive control group is a group administered with PBS as a solvent after nasal inoculation with type 2 severe acute respiratory syndrome coronavirus.
  • the lungs of the positive control group and the CG200745-administered group were removed on the 2nd and 7th days of infection to isolate type 2 severe respiratory syndrome coronavirus, and infect monkey lung cells, Vero cells, to measure the number of colonies made by infected Vero cells. In this way, it was confirmed whether CG200745 inhibited the proliferation of type 2 severe respiratory syndrome coronavirus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement d'une infection par le coronavirus 2 responsable du syndrome respiratoire aigu sévère, la composition pharmaceutique contenant un composé possédant une structure chimique spécifique, un dérivé associé ou un sel pharmaceutiquement acceptable associé en tant que principe actif. Il a été confirmé que la composition pharmaceutique selon la présente invention présente un effet anti-inflammatoire qui soulage les lésions inflammatoires pulmonaires aiguës apparaissant dans un modèle de rongeur avec une infection induite par le coronavirus 2 responsable du syndrome respiratoire aigu sévère, et il a été confirmé que ladite composition supprime la prolifération virale. Par conséquent, la composition pharmaceutique peut traiter ou prévenir efficacement une infection par le coronavirus 2 responsable du syndrome respiratoire aigu sévère.
PCT/KR2021/002974 2021-02-19 2021-03-10 Composition pharmaceutique pour la prévention ou le traitement d'une infection par le coronavirus 2 responsable du syndrome respiratoire aigu sévère WO2022177054A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210022550A KR20220118747A (ko) 2021-02-19 2021-02-19 제2형 중증급성호흡기증후군 코로나바이러스 감염증 예방 또는 치료용 약학 조성물
KR10-2021-0022550 2021-02-19

Publications (1)

Publication Number Publication Date
WO2022177054A1 true WO2022177054A1 (fr) 2022-08-25

Family

ID=82930754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/002974 WO2022177054A1 (fr) 2021-02-19 2021-03-10 Composition pharmaceutique pour la prévention ou le traitement d'une infection par le coronavirus 2 responsable du syndrome respiratoire aigu sévère

Country Status (2)

Country Link
KR (1) KR20220118747A (fr)
WO (1) WO2022177054A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100814092B1 (ko) * 2006-11-03 2008-03-14 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체, 이의제조방법 및 이를 유효성분으로 하는 항암제용 약학조성물
KR20110096028A (ko) * 2008-12-11 2011-08-26 대한민국(관리부서 질병관리본부장) 잠복성 hiv 감염 세포에서 hiv-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제
KR20180136741A (ko) * 2017-06-15 2018-12-26 크리스탈지노믹스(주) 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 또는 그 유도체의 약학적으로 허용 가능한 염 및 그 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100814092B1 (ko) * 2006-11-03 2008-03-14 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체, 이의제조방법 및 이를 유효성분으로 하는 항암제용 약학조성물
KR20110096028A (ko) * 2008-12-11 2011-08-26 대한민국(관리부서 질병관리본부장) 잠복성 hiv 감염 세포에서 hiv-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제
KR20180136741A (ko) * 2017-06-15 2018-12-26 크리스탈지노믹스(주) 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 또는 그 유도체의 약학적으로 허용 가능한 염 및 그 제조방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU KE, ZOU RONGFENG, CUI WENQIANG, LI MEIQING, WANG XUEYING, DONG JUNLIN, LI HONGCHUN, LI HONGPEI, WANG PEIHUI, SHAO XIMING, SU W: "Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2", ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, vol. 3, no. 6, 11 December 2020 (2020-12-11), pages 1361 - 1370, XP055959713, ISSN: 2575-9108, DOI: 10.1021/acsptsci.0c00163 *
TAKAHASHI YOICHIRO, HAYAKAWA AKIRA, SANO RIE, FUKUDA HARUKI, HARADA MEGUMI, KUBO RIEKO, OKAWA TAKAFUMI, KOMINATO YOSHIHIKO: "Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19", SCIENTIFIC REPORTS, NATURE PUBLISHING GROUP, US, vol. 11, no. 1, 1 December 2021 (2021-12-01), US , pages 3379 - 9, XP055959716, ISSN: 2045-2322, DOI: 10.1038/s41598-021-82970-2 *

Also Published As

Publication number Publication date
KR20220118747A (ko) 2022-08-26

Similar Documents

Publication Publication Date Title
WO2014171748A1 (fr) Composition pharmaceutique administrable par voie orale pour la prévention ou le traitement de la kératoconjonctivite sèche, comprenant du rebamipide ou un promédicament correspondant
JP5940607B2 (ja) イミノ糖およびウイルス性疾患を治療する方法
CA2176298C (fr) Traitement a l'aide de fluoroquinolone, en dose unique elevee
EP0689836A1 (fr) Dérivé de spirooxathiolane-quinuclidine pour le traitement de la xérostomie
JP5575246B2 (ja) ポックスウイルス感染の治療方法
WO2023014113A1 (fr) Composition de gouttes oculaires comprenant de la récoflavone destinée au traitement de la xérophtalmie
AU2019327262B2 (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
WO2014054880A1 (fr) Nouvelle composition laxative à stabilité améliorée, contenant du polyéthylène glycol et de la vitamine c
WO2021261837A1 (fr) Composition pharmaceutique orale comprenant du mésylate de nafamostat en tant que substance active
WO2022124525A1 (fr) Composition pharmaceutique pour administration intramusculaire et/ou sous-cutanée, contenant du niclosamide
WO2014209033A1 (fr) Composition pharmaceutique pour prévenir ou traiter une maladie associée aux troubles cognitifs comprenant des composés à base de morpholine ou de pipérazine et du donépézil
WO2022177054A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une infection par le coronavirus 2 responsable du syndrome respiratoire aigu sévère
RU2005129333A (ru) 4-[(2,4-дихлор-5-метоксифенил)амино]-6-алкокси-3-хинолинкарбонитрилы для лечения ишемического повреждения
WO2021187842A1 (fr) Préparation pharmaceutique pour le traitement d'infections au coronavirus du sras, et son utilisation médicale
WO2017200317A1 (fr) Utilisation d'un composé carbamate pour la prévention ou le traitement de la névralgie du trijumeau
WO2021215798A1 (fr) Composition pharmaceutique pour traiter une infection au coronavirus du sras et son utilisation médicale
WO2022114881A1 (fr) Composition pharmaceutique destinée à prévenir ou traiter une plaie ou une cicatrice, comprenant de la benzbromarone
WO2015030504A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de toxoplasmose, comprenant un agent anti-cancer du poumon non à petites cellules comme principe actif
DE2721259A1 (de) Verwendung von benzamiden bei der bekaempfung der symptome, die mit asthma verbunden sind
DE3917233A1 (de) 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
WO2020091512A1 (fr) Composition pharmaceutique destinée à être utilisée dans le traitement de la cardiomyopathie hypertrophique
WO2021251565A1 (fr) Composition pharmaceutique comprenant un composé dérivé de benzimidazole
WO2023219360A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'hépatite b
WO2022255790A1 (fr) Préparation pharmaceutique pour la prévention ou le traitement de la fibrose pulmonaire
WO2023177267A1 (fr) Composition, comprenant un extrait de cinnamomum cassia produit par une technologie innovante d'extraction de ckd (icet), technologie appliquée à celui-ci, pour prévenir, soulager ou traiter les gastrites ou les ulcères peptidiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21926853

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21926853

Country of ref document: EP

Kind code of ref document: A1